Page 2 - Servier Group News Today

Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2...

Private drug developer Servier Group said on Sunday its experimental brain cancer treatment has considerably slowed the progession of a type of brain tumor, a positive in a field that has not seen... | June 4, 2023

(Reuters) - Private drug developer Servier Group said on Sunday its experimental brain cancer treatment has considerably slowed the progession of a ty...

Kansascity.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kansascity.com Daily Mail and Mail on Sunday newspapers.

A French drug developer’s experimental therapy slowed the progression of a type of brain cancer by more than 16 months on average, results that could lead to one of the

David Lee, CEO at Servier Pharmaceuticals, talks about how he set up the French company’s U.S. division, and his goal of reaching $2 billion in...

The French pulmonologist and whistleblower Irène Frachon looks back on her years of battle against the appetite suppressant drug Mediator, which has been blamed for causing hundreds of deaths in France, before it was taken off the market in November 2009.

/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced findings from a...

/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today presented new data at the 64th...

/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, was the recipient of the Patient Champion...